Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate:

Viktor von Wyl,Pascal Benkert,André Moser,Johannes Lorscheider,Bernhard F. Décard,Peter Hänni,Carmen Lienert,Jens Kuhle,Tobias Derfuss,Ludwig Kappos,Özgür Yaldizli

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate:

2020

Viktor von Wyl
Pascal Benkert
André Moser
Johannes Lorscheider
Bernhard F. Décard
Peter Hänni
Carmen Lienert
Jens Kuhle
Tobias Derfuss
Ludwig Kappos
Özgür Yaldizli

Background:Disability progression independent of relapses (PIRA) has been described as a frequent phenomenon in relapsing-remitting multiple sclerosis (RRMS).Objective:To compare the occurrence of ...

Keywords:

Oncology
Fingolimod
interferon beta
disability progression
Internal medicine
Pathology
Glatiramer acetate
Medicine
relapsing remitting
Multiple sclerosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations